Page last updated: 2024-09-03

marimastat and Liver Steatosis

marimastat has been researched along with Liver Steatosis in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Meijer, VE; Le, HD; Meisel, JA; Popov, Y; Puder, M; Sharma, AK	1
Alwayn, IP; Andersson, C; Arsenault, DA; Bistrian, BR; Gura, KM; Lee, S; Moses, M; Nose, V; Puder, M; Zauscher, B	1

Other Studies

2 other study(ies) available for marimastat and Liver Steatosis

Article	Year
Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PloS one, 2011, Volume: 6, Issue:9 Topics: ADAM Proteins; ADAM17 Protein; Adipokines; Animals; Biomarkers; Diet, High-Fat; Fatty Acids; Fatty Liver; Feedback, Physiological; Gene Expression Regulation; Hepatectomy; Hydroxamic Acids; Insulin; Insulin Resistance; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Protease Inhibitors; RNA, Messenger; Time Factors; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome	2011
Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. American journal of physiology. Gastrointestinal and liver physiology, 2006, Volume: 291, Issue:6 Topics: Animals; Dietary Carbohydrates; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Hydroxamic Acids; Interleukin-6; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; PPAR alpha; Treatment Outcome	2006

Article

Year

Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice.

PloS one, 2011, Volume: 6, Issue:9

Topics: ADAM Proteins; ADAM17 Protein; Adipokines; Animals; Biomarkers; Diet, High-Fat; Fatty Acids; Fatty Liver; Feedback, Physiological; Gene Expression Regulation; Hepatectomy; Hydroxamic Acids; Insulin; Insulin Resistance; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Protease Inhibitors; RNA, Messenger; Time Factors; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome

2011

Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.

American journal of physiology. Gastrointestinal and liver physiology, 2006, Volume: 291, Issue:6

Topics: Animals; Dietary Carbohydrates; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Hydroxamic Acids; Interleukin-6; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; PPAR alpha; Treatment Outcome

2006